Readout AI is a technology company.
Readout AI has raised $2.0M across 1 funding round.
Readout AI has raised $2.0M in total across 1 funding round.
Readout AI is an AI-powered platform that automates clinical trial data analysis, including data cleaning, statistical analysis, and report generation, reducing task times by up to 85%.[1][2] It serves pharmaceutical companies, biotech firms, and clinical research organizations (CROs) by streamlining workflows across the trial lifecycle—from recruitment funnel analysis to clinical study report (CSR) generation—while prioritizing data privacy through automatic deletion of uploaded data.[1][2] With $1.7 million in funding from investors like Meridian Street Capital and a lean team of 3 employees, the company has shown strong early momentum, winning the SCDM 2024 Innovator Start-up of the Year award for its efficiency gains in data management and biometrics.[1][2]
Readout AI emerged to address inefficiencies in clinical trial data management, with CEO Matthew Michelson leading the effort to automate tedious tasks like data quality assessment, medical monitoring, site comparison, database lock, and rote reporting such as baseline characteristics and adverse events narratives.[2] The company's idea stems from leveraging AI models to speed up cycle times by 85% across trial stages and therapy areas, emphasizing privacy (no data storage or model training on user data) and ease of use for rapid adoption.[2] Pivotal early traction includes securing $1.7 million in funding from Meridian Street Capital and clinching the inaugural SCDM 2024 Innovation Award, highlighting its alignment with industry needs for faster therapy development.[1][2]
Readout AI rides the wave of AI in biotech and clinical trials, where mounting pressures for faster drug development amid rising trial costs (often exceeding $1-2 billion per therapy) demand automation.[2] Timing is ideal as regulatory bodies like the FDA push for efficient data handling, and AI advancements enable precise, compliant analysis without compromising patient privacy—key amid growing data volumes from diverse trials.[1][2] Market forces like talent shortages in biostatistics and the need for diversity in trial populations favor Readout AI, positioning it to influence the ecosystem by accelerating therapies to market and enabling smaller biotechs to compete.[1][2]
Readout AI is primed for expansion with its validated efficiency and award-winning status, likely pursuing Series A funding to scale features like advanced analytics or integrations with electronic data capture systems.[1][2] Trends in multimodal AI, decentralized trials, and real-world evidence will shape its path, amplifying impact as pharma adopts AI roadmaps for worker augmentation.[2][5] Its influence could evolve from niche innovator to ecosystem standard, powering faster, more inclusive clinical trials and tying back to its core promise: turning data bottlenecks into breakthroughs for therapies that reach patients sooner.[2]
Readout AI has raised $2.0M in total across 1 funding round.
Readout AI's investors include Curie.Bio, First Round Capital, i/o Ventures, Meridian Street Capital, Niu Ventures, Operator Partners, Refactor Capital, SV Angel, Threshold Ventures, Transformation Capital, Venture Catalysts | India's First Integrated Incubator, Aaron Patzer.
Readout AI has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $2.0M Seed | Curie.Bio, First Round Capital, i/o Ventures, Meridian Street Capital, Niu Ventures, Operator Partners, Refactor Capital, SV Angel, Threshold Ventures, Transformation Capital, Venture Catalysts | India's First Integrated Incubator, Aaron Patzer, Vivek Garipalli |